Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 138 of 1,261
  1. US 11897879

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  2. US 11897873

    Kappa opioid receptor antagonists and products and methods related thereto

    BLACKTHORN THERAPEUTICS, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  3. US 11898180

    Compositions and methods for amino acid depletion therapy

    Avalon Polytom (HK) Limited · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  4. US 11897969

    Inhibition of oxidation-specific epitopes to treat ischemic reperfusion injury

    The Regents of the University of California · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  5. US 11898158

    Methods and compositions for the treatment of lysosomal storage diseases

    Sangamo Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  6. US 11896558

    Use of an RXR agonist and taxanes in treating Her2+ cancers

    The Board of Regents of the University of Texas System · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  7. US 11897845

    Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  8. US 11896617

    Polynucleotides encoding rituximab-resistant chimeric antigen receptors

    Allogene Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  9. US 11896643

    Fibroblast binding agents and use thereof

    Orionis Biosciences, Inc · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  10. AU 2022206771

    Drug conjugates comprising antibodies against Claudin 18.2

    ASTELLAS PHARMA INC [JP] · Granted Feb 8, 2024 · Expires Feb 3, 2044

    granted
  11. US 11890320

    CLEC11A is a bone growth agent

    The Board of Regents of the University of Texas System · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  12. US 11890307

    Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

    Finch Therapeutics Holdings LLC · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  13. US 11891638

    Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)

    Northwestern University · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  14. US 11891442

    Compositions and methods for treating age-related diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  15. US 11890225

    Devices and methods for slurry generation

    MIRAKI INNOVATION THINK TANK LLC · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  16. US 11891360

    Glycosylated psilocybin derivatives and methods of using

    Enveric Biosciences Canada Inc. · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  17. US 11890289

    Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

    Corcept Therapeutics Incorporated · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  18. US 11890272

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  19. US 11890353

    Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies

    Northwestern University · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  20. US 11890346

    Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein

    Northwestern University · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  21. US 11890340

    Use of epithelial membrane protein 2 [EMP2] targeting agents in treating lung disorders

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  22. US 11890344

    One-step processing of hydrogels for mechanically robust and chemically desired features

    The Board of Regents of the University of Texas System · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  23. US 11890308

    Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them

    Finch Therapeutics Holdings LLC · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  24. US 11891402

    Compositions and methods for treating cancer

    The Regents of the University of California · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.